Since our study lacked disease-specific control groups, such as patients with T2DM alone or COVID-19 alone, we cannot determine whether the observed elevations in galectin-3 and sICAM-1 are specific to the combination of these two conditions or primarily driven by one of them. The gene discussed is LGALS3; the disease is COVID-19.